141 related articles for article (PubMed ID: 19793349)
1. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity.
Chen G; Wei DP; Jia LJ; Tang B; Shu L; Zhang K; Xu Y; Gao J; Huang XF; Jiang WH; Hu QG; Huang Y; Wu Q; Sun ZH; Zhang JF; Hua ZC
Cancer Sci; 2009 Dec; 100(12):2437-43. PubMed ID: 19793349
[TBL] [Abstract][Full Text] [Related]
2. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
3. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
7. Chloroquine enhanced the anticancer capacity of VNP20009 by inhibiting autophagy.
Zhang X; Xu Q; Zhang Z; Cheng W; Cao W; Jiang C; Han C; Li J; Hua Z
Sci Rep; 2016 Jul; 6():29774. PubMed ID: 27412722
[TBL] [Abstract][Full Text] [Related]
8. Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector.
Zheng LM; Luo X; Feng M; Li Z; Le T; Ittensohn M; Trailsmith M; Bermudes D; Lin SL; King IC
Oncol Res; 2000; 12(3):127-35. PubMed ID: 11216671
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
10. Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.
Coutermarsh-Ott SL; Broadway KM; Scharf BE; Allen IC
Oncotarget; 2017 May; 8(20):33601-33613. PubMed ID: 28431394
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
12. Tumor-targeting Salmonella typhimurium, a natural tool for activation of prodrug 6MePdR and their combination therapy in murine melanoma model.
Chen G; Tang B; Yang BY; Chen JX; Zhou JH; Li JH; Hua ZC
Appl Microbiol Biotechnol; 2013 May; 97(10):4393-401. PubMed ID: 22868826
[TBL] [Abstract][Full Text] [Related]
13. Toxicology and efficacy of tumor-targeting
Zhang Y; Cao W; Toneri M; Zhang N; Kiyuna T; Murakami T; Nelson SD; Dry SM; Li Y; Li S; Wang X; Ma H; Singh AS; Eilber FC; Hoffman RM; Zhao M
Oncotarget; 2017 Aug; 8(33):54616-54628. PubMed ID: 28903369
[No Abstract] [Full Text] [Related]
14. [Anti-tumor effect and impact on tumor immune microenvironment of tumor-targeted Salmonella VNP20009].
Han YH; Lai XH; Le ZW; Hua ZC
Yao Xue Xue Bao; 2016 Sep; 51(9):1417-22. PubMed ID: 29924525
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Targeting Salmonella typhimurium A1-R Promotes Tumoricidal CD8
Murakami T; Hiroshima Y; Zhang Y; Zhao M; Kiyuna T; Hwang HK; Miyake K; Homma Y; Mori R; Matsuyama R; Chishima T; Ichikawa Y; Tanaka K; Bouvet M; Endo I; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):634-639. PubMed ID: 28628234
[TBL] [Abstract][Full Text] [Related]
16. Oral Delivery of Tumor-Targeting Salmonella to Treat Cancer in Mice.
Wei D; Jia L
Methods Mol Biol; 2016; 1409():25-33. PubMed ID: 26846799
[TBL] [Abstract][Full Text] [Related]
17. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.
Chen J; Yang B; Cheng X; Qiao Y; Tang B; Chen G; Wei J; Liu X; Cheng W; Du P; Huang X; Jiang W; Hu Q; Hu Y; Li J; Hua ZC
Cancer Sci; 2012 Feb; 103(2):325-33. PubMed ID: 22054098
[TBL] [Abstract][Full Text] [Related]
18. H
Fan Y; Bai T; Tian Y; Zhou B; Wang Y; Yang L
Drug Des Devel Ther; 2021; 15():209-222. PubMed ID: 33488068
[TBL] [Abstract][Full Text] [Related]
19. Oral delivery of the Sj23LHD-GST antigen by Salmonella typhimurium type III secretion system protects against Schistosoma japonicum infection in mice.
Chen G; Dai Y; Chen J; Wang X; Tang B; Zhu Y; Hua Z
PLoS Negl Trop Dis; 2011 Sep; 5(9):e1313. PubMed ID: 21909450
[TBL] [Abstract][Full Text] [Related]
20. Vaccination of chickens with strain CVL30, a genetically defined Salmonella enteritidis aroA live oral vaccine candidate.
Cooper GL; Venables LM; Woodward MJ; Hormaeche CE
Infect Immun; 1994 Nov; 62(11):4747-54. PubMed ID: 7927750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
